Ausgabe 2/2017
Inhalt (14 Artikel)
Dupilumab Use in Atopic Conditions and Its Side Effects
Athanasios Tsianakas, Thomas A. Luger
Omalizumab for Chronic Urticaria: Aftermarket Reports of Efficacy and Side Effects
Misbah Noshela Ghazanfar, Simon Francis Thomsen
Updates in the Approach to the Patient with Purpura
Ryan Arakaki, Lindy Fox
Cutaneous Lymphoma—Inpatient Considerations
Kerry Heitmiller, Jeffrey Barnes, Steven T. Chen
Cutaneous Manifestations of Connective Tissue Disease in the Inpatient Setting
Yahya Argobi, Gideon P. Smith
Cutaneous Side Effects and Drug Interactions Related to Immunosuppressive Therapy in Solid Organ Transplantation
Allison Gregory, Marianna Leung, Gary Nussbaumer, Sheila Au
The Role of the Skin and Gut Microbiome in Psoriatic Disease
Di Yan, Naiem Issa, Ladan Afifi, Caleb Jeon, Hsin-Wen Chang, Wilson Liao
Autoimmunity in Psoriasis: Evidence for Specific Autoantigens
Jason E. Hawkes, Jose A. Gonzalez, James G. Krueger
TNF Inhibitors for Psoriasis and Psoriatic Arthritis
Leah A. Cardwell, Brandy Sullivan, Emilia Baran, Elias Oussedik, Steven R. Feldman
Update on IL-17 Inhibitors for Psoriasis
Adriane A Levin, Jeffrey M Sobell
Update on Comorbidities in Psoriasis
Anna Maria Andersson, Lone Skov, Jacob P. Thyssen, Alexander Egeberg
Topical Therapy of AD: How to Reach Better Results
Alexandra Walter, Marlene Seegräber, Christoph Rothenberger, Jerome Srour, Andreas Wollenberg
Atopic Dermatitis 2.0: the Long and Tedious Road to Precision Medicine
Thomas Bieber
Systemic Therapy of Atopic Dermatitis: When, How, for How Long?
Kunal Malik, Emma Guttman-Yassky